MENU
+Compare
FMED
ETF ticker: NASDAQ
AS OF
Aug 29, 11:47 AM (EDT)
Price
$24.42
Change
-$0.10 (-0.41%)
Net Assets
54.09M

FMED stock forecast, quote, news & analysis

The investment seeks long-term growth of capital... Show more

Category: #Health
FMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for FMED with price predictions
Aug 28, 2025

Momentum Indicator for FMED turns positive, indicating new upward trend

FMED saw its Momentum Indicator move above the 0 level on August 13, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator turned positive. In of the 38 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for FMED just turned positive on August 14, 2025. Looking at past instances where FMED's MACD turned positive, the stock continued to rise in of 22 cases over the following month. The odds of a continued upward trend are .

FMED moved above its 50-day moving average on August 13, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FMED crossed bullishly above the 50-day moving average on August 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in of 124 cases, the price rose further within the following month. The odds of a continued upward trend are .

FMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 96 cases where FMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for FMED moved out of overbought territory on August 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Regeneron Pharmaceuticals (NASDAQ:REGN), Edwards Lifesciences Corp (NYSE:EW), Align Technology (NASDAQ:ALGN), Exact Sciences Corp (NASDAQ:EXAS).

Industry description

The investment seeks long-term growth of capital. The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.

Market Cap

The average market capitalization across the Fidelity Disruptive Medicine ETF ETF is 35.48B. The market cap for tickers in the group ranges from 526.32M to 656.17B. LLY holds the highest valuation in this group at 656.17B. The lowest valued company is AGL at 526.32M.

High and low price notable news

The average weekly price growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was 9%. For the same ETF, the average monthly price growth was 86%, and the average quarterly price growth was 149%. PHR experienced the highest price growth at 13%, while BNTX experienced the biggest fall at -8%.

Volume

The average weekly volume growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was -16%. For the same stocks of the ETF, the average monthly volume growth was -42% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 100
Price Growth Rating: 55
SMR Rating: 100
Profit Risk Rating: 84
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
FMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
82 Devonshire StreetBoston
Phone
N/A
Web
www.institutional.fidelity.com